Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia

By on    Pharma Industry News  

Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia

Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for treating anemia associated with non-transfusion-dependent (NTD) beta thalassemia in adult patients. Presently, Reblozyl is approved in the European Union (EU), the US, and Canada for addressing anemia resulting from transfusion-dependent beta thalassemia and transfusion-dependent lower-risk myelodysplastic syndromes. […]

EC approves Reblozyl for transfusion-dependent anemia in adults

By on    Pharma Industry News  

EC approves Reblozyl for transfusion-dependent anemia in adults

Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the treatment of transfusion-dependent anemia in adult patients. The approval of Reblozyl is for transfusion-dependent anemia caused by very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had […]